PRTC News and Press, PureTech Health plc From 10/26/22

Summary During the third quarter of 2022, the Miller Opportunity Equity strategy generated a total return of -4.62% net of fees. Using a three-factor performance attribution model, allocation, and selection effects contributed to the strategy’s outperformance which was part...

If you’re looking for the best penny stocks to buy, you likely understand the disconnect between broader trends and cheap stocks. Since penny stocks move independently, most of the time, you’re sure to find at least a few companies to follow. Today this became more evi...

Update 10:02am : Updates shares. PureTech Health ( NASDAQ: PRTC ) dropped 21% after it confirmed receiving a non-binding proposal from Nektar Therapeutics ( NASDAQ: NKTR ) to combine. Nektar fell 4.3%. PureTech and Nektar remain in discussions regar...

PureTech Health ( NASDAQ: PRTC ) dropped 20% in premarket trading after it confirmed receiving a non-binding proposal from Nektar Therapeutics ( NASDAQ: NKTR ) to combine. PureTech and Nektar remain in discussions regarding the proposal, according to 6-K fili...

PureTech Health ( NASDAQ: PRTC ) soared 9.3% on some speculation that the company may be a takeover target. People following the matter have heard some speculation that PureTech ( PRTC ) received some takeover interest, according to a Betaville item. Developing...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, and Julie Krop, M.D., ...

LYT-100 was well-tolerated compared to pirfenidone in a healthy older adult crossover trial, informing dose selection for recently initiated trial in IPF PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company...

The following slide deck was published by PureTech Health plc in conjunction with this event. For further details see: PureTech Health (PRTC) Investor Presentation - Slideshow

PureTech press release ( NASDAQ: PRTC ): 1H GAAP EPS of -$0.10. Revenue of $7.03M (+20.4% Y/Y). Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4M and Consolidated Cash and Cash Equivalents of $365.9M as of June 30, 2022, excluding u...

Strategic partnership created to develop and license a new vocal biomarker detection and monitoring capability for COPD in India PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a biotherapeutics company, today anno...